Organon & Co. OGN
Composite 50/100; the shares have moved about 72% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 16/100 — a strong mark against it.
Momentum ranks 79/100 — a strong point in its favour. Valuation ranks 72/100 — a moderate point in its favour. Quality ranks 54/100 — a slight point in its favour.
Growth ranks 16/100 — a strong mark against it. Balance-sheet strength ranks 31/100 — a moderate mark against it. Income ranks 40/100 — a slight mark against it.
What the company does Organon & Co. (OGN) is a global women’s health and biosimilars company, marketing contraceptives (Nexplanon, NuvaRing), fertility drugs (Follistim AQ), postpartum hemorrhage treatment (Jada), biosimilars in immunology and oncology (e.g., Brenzys, Ontruzant), and cholesterol/antihypertensive therapies (Zetia, Cozaar).
Key financials OGN posts a 34.1% ROE and 5.9% ROA, with gross/operating/net margins of 53.8%/18.7%/4.0%. Revenue fell -3.5% while EPS rose 66.7%. Debt/Equity is 9.49x and interest coverage 2.09x; the current ratio is 1.97x.
Stock health Momentum is mixed: +2.46% over 3m, +58.24% over 6m, +36.20% over 12m, and -0.33% below its 52-week high. RSI(14) is 63.00. Sideravia scores Valuation 77.8 and Momentum 74.9, but Strength 30.9 and Growth 43.1 lag.
Price vs fair value The stock trades at a discount of 194.80% versus our fair-value estimate of 39.97 and at a PREMIUM of 17.77% versus the analyst 12-month target of 11.15. - Q2 earnings lagged estimates, pressuring sentiment (Zacks 2026-07-31). - Q2 results were compared to estimates, highlighting mixed execution (Zacks 2026-07-31). - Recent attention suggests investor interest but also implies valuation scrutiny (Zacks 2026-07-28).
Looking forward Forward P/E of 5.09x and EV/EBITDA of 7.91x imply deep value if execution improves, while low dividend yield (0.6%) and high leverage (Debt/EBITDA 4.67x) remain risks. Analysts’ 11.15 target suggests limited near-term upside unless growth accelerates.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.